Drug Development

ASPIRE to Innovate Postdoctoral Fellow Catherine Leasure is the co-author of a comment article published this month in Nature Reviews Bioengineering addressing the pressing obstacle faced by modern drug development: worryingly poor success rates of pharmaceuticals progressing to clinical phases. Read More

Research led by David Merryman, a professor of biomedical engineering, pharmacology and medicine who holds the Walters Family Chair, has resulted in the development of VU6047534, a new drug that treats pulmonary arterial hypertension—a type of high blood pressure that affects arteries in the lungs and in the heart—without serious neurological side effects. Merryman conducted... Read More

The Office of the Vice Provost for Research and Deerfield Management announce the inaugural request for proposals for Ancora Innovation, LLC, with a due date of June 4. An RFP information session is scheduled from 2 to 3:30 p.m. Friday, April 27, at Sarratt Student Center, Room 325. Read More

Two brain signaling pathways have overlapping functions in regulating anxiety, suggesting that therapeutics aimed at one or the other will impact both. Read More

A new protein structure may guide the development of Alzheimer's therapeutics. Read More

Anti-cancer drugs are typically tested on one type of cancer at a time. But an international consortium of cancer investigators, including Vanderbilt-Ingram Cancer Center (VICC) researchers, simultaneously tested an existing therapy in patients with several different forms of cancer that all exhibit the same tumor gene mutation. Read More

Vanderbilt physicist John Wikswo reported significant progress toward creating “homo minutus” – a human-on-a-chip that can be used to test drugs and toxins – on Mar. 26 at the Society of Toxicology meeting in Phoenix. Read More